Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers
| Authors | Mukhopadhyay S, Goswami D, Adiseshaiah PP, Burgan W, Yi M, Guerin TM, Kozlov SV, Nissley DV, McCormick F |
|---|---|
| Details | Cancer Res. 2020 Jan 7. pii: canres.1363.2019. doi: 10.1158/0008-5472.CAN-19-1363 |
| DOI | 10.1158/0008-5472.CAN-19-1363 |
| Topics | |
| Keywords | |
| Source | View on PubMed |
Quite the idea to treat difficult cancers: restrict stress-granule formation with a small molecule (to prevent chemoresistance) then hit with chemo.